Landos Biopharma Announces First Patient Dosed in Global Phase 2 Clinical Trial of BT11 in Mild to Moderate Ulcerative Colitis

Global clinical trial underway in 11 countries including U.S. European and Eastern European sites to evaluate safety efficacy and tolerability of orally administered gutrestricted LANCL2 agonist BT11 in patients with mild to moderate ulcerative colitis La...